Ascletis' ASC30 Shows 1.7% Placebo-Adjusted HbA1c Reduction at 12 Weeks

Ascletis said its oral GLP-1 candidate ASC30 reduced HbA1c by a placebo-adjusted 1.7% at 12 weeks in a U.S. Phase II study in participants with diabetes.